Literature DB >> 18606774

Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.

J Robert Putnak1, Rafael de la Barrera, Timothy Burgess, Jorge Pardo, Francis Dessy, Dirk Gheysen, Yves Lobet, Sharone Green, Timothy P Endy, Stephen J Thomas, Kenneth H Eckels, Bruce L Innis, Wellington Sun.   

Abstract

Plaque reduction neutralization tests (PRNTs) are commonly used for measuring levels of dengue virus (DENV) neutralizing antibodies. However, these assays lack a standardized format, generally have a low sample throughput, and are labor-intensive. The objective of the present study was to evaluate two alternative DENV neutralizing antibody assays: an enzyme-linked immunosorbent assay-based microneutralization (MN) assay, and a fluorescent antibody cell sorter-based, DC-SIGN expresser dendritic cell (DC) assay. False-positive rates, serotype specificity, reproducibility, sensitivity, and agreement among the assay methods were assessed using well-characterized but limited numbers of coded test sera. Results showed that all three assays had false-positive rates of less than 10% with titers near the cut-off and generally below the estimated limits of detection. All three methods demonstrated a high degree of specificity and good agreement when used to assay sera and serum mixtures from monovalent vaccinees and sera from patients after primary natural infection, with the only notable exception being moderate-to-high neutralizing antibody titers against DENV 2 measured by PRNT in a mixture containing only DENV 3 and DENV 4 sera. The MN and DC assays demonstrated good reproducibility. All three assays were comparable in their sensitivity, except that the PRNT was less sensitive for measuring DENV 4 antibody, and the MN and DC assays were less sensitive for measuring DENV 2 antibody. However, when used to test sera from persons after tetravalent DENV vaccination or secondary DENV infection, there was poor specificity and poor agreement among the different assays.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606774

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  27 in total

1.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

2.  Antibody recognition of the dengue virus proteome and implications for development of vaccines.

Authors:  Stefan Fernandez; Emily D Cisney; Alexander P Tikhonov; Barry Schweitzer; Robert J Putnak; Monika Simmons; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

3.  Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Authors:  Matthew R Vogt; Kimberly A Dowd; Michael Engle; Robert B Tesh; Syd Johnson; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

4.  Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.

Authors:  Willem G van Panhuis; Robert V Gibbons; Timothy P Endy; Alan L Rothman; Anon Srikiatkhachorn; Ananda Nisalak; Donald S Burke; Derek A T Cummings
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

5.  Dengue virus markers of virulence and pathogenicity.

Authors:  Rebeca Rico-Hesse
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

6.  Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy.

Authors:  Katherine M Smith; Kavita Nanda; Carla J Spears; Amanda Piper; Mariana Ribeiro; Michelle Quiles; Caitlin M Briggs; Gwynneth S Thomas; Malcolm E Thomas; Dennis T Brown; Raquel Hernandez; Victoria McCarl
Journal:  Am J Trop Med Hyg       Date:  2012-08-13       Impact factor: 2.345

7.  Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes.

Authors:  Kimberly Mattia; Bridget A Puffer; Katherine L Williams; Ritela Gonzalez; Meredith Murray; Emily Sluzas; Dan Pagano; Sandya Ajith; Megan Bower; Eli Berdougo; Eva Harris; Benjamin J Doranz
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

8.  A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.

Authors:  Annie Hoi Yi Chan; Hwee Cheng Tan; Angelia Yee Chow; Angeline Pei Chiew Lim; Shee Mei Lok; Nicole J Moreland; Subhash G Vasudevan; Paul A MacAry; Eng Eong Ooi; Brendon J Hanson
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

9.  Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.

Authors:  Tatyana M Timiryasova; Matthew I Bonaparte; Ping Luo; Rebecca Zedar; Branda T Hu; Stephen W Hildreth
Journal:  Am J Trop Med Hyg       Date:  2013-03-04       Impact factor: 2.345

10.  A novel reporter system for neutralizing and enhancing antibody assay against dengue virus.

Authors:  Ke-Yu Song; Hui Zhao; Zhen-You Jiang; Xiao-Feng Li; Yong-Qiang Deng; Tao Jiang; Shun-Ya Zhu; Pei-Yong Shi; Bo Zhang; Fu-Chun Zhang; E-De Qin; Cheng-Feng Qin
Journal:  BMC Microbiol       Date:  2014-02-18       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.